Drug Trial Radar · NCT07414953
A Phase Ib Study of HS-10504 Combined Therapy in NSCLC
Last checked: Nov 19, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Mar 30, 2026
Primary completion
Apr 30, 2027
Study completion Nov 30, 2028
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-10504 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Conditions
- Lung Cancer
Interventions
HS-10504Drug
HS-10504 administered orally every day
SHR-A2009Drug
SHR-A2009 administered intravenously
HS-20122Drug
HS-20122 administered intravenously
HS-20117Drug
HS-20117 administered intravenously
SHR-1826Drug
SHR-1826 administered intravenously
SHR-A2102Drug
SHR-A2102 administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- RP2D for CombinationTime frame: Through the full duration of this trial, approximately 2 years
- ORRTime frame: Through the full duration of this trial, approximately 2 years
- TEAETime frame: Through the full duration of this trial, approximately 2 years
- TRAETime frame: Through the full duration of this trial, approximately 2 years
- SAETime frame: Through the full duration of this trial, approximately 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.